Bionano Announces Prototype for its Next Single Molecule Imaging System for OGM
December 29 2021 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of the leading
software solutions for visualization, interpretation and reporting
of genomic data, today announced that it has completed the first
prototype for its next single molecule imaging system for OGM. The
prototype is being used to integrate and test the key engineering
designs of a new instrument and consumable intended to meet the
needs of high volume users. The commercial system based on this
prototype is expected to be released in the first half of 2023.
We believe OGM provides the most comprehensive, reliable and
cost-effective solution for detecting structural variations
(SVs). OGM is a workflow comprised of four proprietary
stages: (i) ultra-high molecular weight DNA isolation; (ii)
sequence-specific DNA labeling; (iii) single molecule linearization
& imaging; and (iv) data processing and analysis. The third
stage creates the molecule images and sequence motif patterns that
are used to reveal SVs. This stage also sets the limit on the
number of samples that can be processed per day. The throughput of
the current Saphyr system is designed for the volumes encountered
by academic medical centers doing standard clinical research in
genomics, but large reference laboratories and contract research
organizations (CROs) with higher volumes require an instrument with
higher throughput capabilities.
Compared to the Saphyr system, which images DNA at a rate of
approximately 205 Gbp per hour, the new system is expected to image
nearly 820 Gbp per hour. The new instrument is designed to be
configurable into an array of up to four instruments processing
samples in parallel approximately six months after initial release.
Other anticipated features of the new system include a new
consumable design, higher capacity carousel for staging samples to
be imaged and updated optical components all in a space-efficient
benchtop footprint.
The new imaging system will also incorporate features designed
to make high throughput workflows more flexible, allowing for data
collection to start without needing to wait for multiple samples
being available, enabling high-coverage cancer experiments to be
run next to lower coverage constitutional experiments and the
ability to prioritize samples to be run ahead of all others. This
flexibility is expected to surpass that of peer sequencing systems,
where getting this flexibility often means waiting for enough
samples to fill a flow cell or paying a significant per sample
premium to have a sample consume more of a consumable.
Erik Holmlin, PhD, president and CEO of Bionano said, “I want to
congratulate our team for finishing this prototype on schedule.
With expected integration of OGM into NxClinical in 2022, the
leading software solution for visualization, interpretation and
reporting of single nucleotide variants and copy number variants
from next-generation sequencing and microarrays, we believe this
new system and consumable will be the next major additions to our
list of products for the growing community of OGM users. I am
impressed with the innovation our team has brought to the project
and I am eagerly awaiting their progress in 2022.”
Mark Oldakowski, Chief Operating Officer of Bionano said,
“Guided by our intimate knowledge of our customers’ needs, the
progress this team has made has been spectacular. Next year, I look
forward to sharing additional amazing advancements for this new
imaging system we hope will delight our customers.”
Prototype photos of the next single molecule imaging system for
OGM will be made available on Bionano’s social media channels on
December 31, 2021.
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, [timing for
anticipated launch of the commercial system;] [whether Saphyr will
remain available for purchase after the new system is released;]
the anticipated performance of the new system and its anticipated
features, as well as anticipated performance of the new system
relative to competitor sequencing systems; and timing of
advancements in the new system. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive products,
technologies or improvements in existing technologies; a reduction
in large reference laboratories and CROs seeking to bring OGM
in-house; delays in the advancement and development of the
prototype into a commercially available system; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; the ability of medical and research institutions to obtain
funding to support adoption or continued use of our technologies;
and the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2020 and
in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the
receipt of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024